Hepatitis: A Silent Killer

With the sixth highest population in the world, Pakistan is a developing country that is severely impacted by Hepatitis. According to WHO, 150,000 individuals in Pakistan succumb to the disease every year, making public education about it urgently necessary. Therefore, following are key facts to remember on World Hepatitis day: What is Hepatitis? It is an inflammatory disorder of the liver, one of the most vital organs of the body. Its healthy function is critically necessary for survival, and is severely compromised in this condition. Hepatitis can harm the liver to the point where it develops scarring even cancer, and ultimately leads to death. What are its root causes? The most common causes of the condition are infections of Hepatitis viruses A, B, C, D and E which lead to viral hepatitis. In addition, alcohol/drug toxicity and certain autoimmune disorders contribute significantly to its prevalence. How is the virus transmitted? Viral hepatitis is of 5 distinct types according to the agent causing it and consequently, each type gets transmitted in different ways. Hepatitis A: It is primarily transmitted by the fecal-oral route, but inadequately treated water and close physical contact with an infected person are also to be blamed for its spread. It is a self limiting disease with only supportive therapy given through the disease period. Hepatitis B: It is a potentially life-threatening type that can be transmitted from an infected mother to a child (at the time of delivery/perinatal transmission) or by exposure to infected body fluids (such as saliva, vaginal and seminal fluids) including blood (by any type of needle stick injury). Hepatitis C: It spreads through transfusion of unscreened blood/blood products, using of poorly sterilized medical equipment, and re-using needles. Infection with this type of Virus is usually chronic and damages the liver over months and years destroying the structure and function of the organ. Hepatitis D: A very significant component in its occurrence is the presence of hepatitis B virus in the body; hence needle stick injuries are typically the cause of hepatitis B and D co-infection. Hepatitis E: Its spread is essentially linked to poor hygiene. It also spreads via the faeco- oral route like Hepatitis A. Usually through contaminated drinking water. Infection with this type of virus is also usually self limiting with only supportive therapy given through the disease. What are its symptoms? Even though Hepatitis is of multiple different types, yet symptoms are quite similar overall. An infected person usually presents to the hospital with complaints of: Fever Abdominal discomfort Dark colored urine Jaundice Fatigue Nausea Loss of appetite which eventually leads to anorexia. How is it diagnosed? Clinically, similarities in signs and symptoms make it challenging to differentiate one form of viral hepatitis from another. However, several laboratory techniques, such as RT-PCR, RNA assays and testing blood for antibodies against a particular virus, are beneficial in this regard. Additionally, tests might reveal a person’s hepatitis immunity or the length of their infection. Is hepatitis treatable? Yes, the treatment depends upon the severity and type of infection. A mild infection only requires antiviral and symptomatic therapy, whilst a fulminant infection may potentially necessitate a liver transplant. Furthermore, dosage and duration of the therapy vary depending upon presence of any other health conditions, and it is advised to avoid certain medications (acetaminophen) and alcohol during the treatment. Hepatitis A and E: Symptomatic therapy is sufficient for these infections because they resolve on their own. Hepatitis B: It is advised to administer oral antiviral medications (including interferon alpha-2b and lamivudine). Hepatitis C: The medications used to treat chronic hepatitis C (pegylated interferon alpha-2a and 2b) are different from those used to treat acute forms of the infection (interferon alpha-2b). Hepatitis D: Pegylated interferon-alpha is used to treat its infection and it is crucial to maintain the therapy for 48 weeks regardless of patient’s response. How can we prevent hepatitis? In recent years, cases of hepatitis have been surging, especially in developing nations; therefore, it is crucial to take the right prophylactic steps on a personal and organizational basis. Several preventative measures include: The availability of clean drinking water Proper sewage disposal Blood screening Good personal hygiene Proper cleaning of wounds Avoid re-using needles. Availability of vaccines Vaccines are available only against hepatitis A and B viruses, which can be administered as a combination as well. Separately, Hepatitis B vaccine can be given within the first 24 hours of life while first dose of hepatitis A vaccine is typically given between the ages of 12 to 23 months. Considering the high rates of illness and morbidity, especially in pregnant women and infants, it has become essential to take rapid action for the control of hepatitis. Hepatitis – Basil Saleem, SMDC Literary Society
Medical Observer ship Visit Johns Hopkins

Shahid Husain Foundation, Shalamar Hospital, and Johns Hopkins Medicine International (JHMI) are working to build Pakistan’s first Women’s Health Center. Two doctors – Dr. Sadaf Ishaq, Asst. Professor of Surgery / Oncology and Dr. Eisha Tahir, Assistant Professor of Radiology – from Shalamar Hospital, visited the JHMI, USA, in the first week of June 2022 for Medical Observership training to learn about best practices. Recently they returned after their first observership visit and delivered presentations on their learning experience and their plan to improve their respective departments for the development of the Women Health Center. Here’s what Dr. Sadaf and Dr. Eisha learned from their Medical Observership visit to Johns Hopkins Medical International (JHMI), USA. “My visit to JHMI was centered in the breast imaging unit at the Johns Hopkins main, Green Spring Station, and White Marsh Center. I shadowed Dr. Emily Ambinder, Dr. Phil Di Carlo, and Dr. Babita Panigrahi. The focus of this visit was learning about the latest imaging modalities and interventional procedures related to breast cancer screening & diagnosis. During observership, I primarily concentrated on screening & diagnostic mammography reporting, breast MRI reporting, stereotactic biopsy, clipping and wire localization, and MR-guided biopsy and clipping. JHMI is equipped with the latest imaging modalities and follows the ACR guidelines in their diagnostic workup and follow-up. “My clinical observership was in the breast centers of Johns Hopkins Hospitals at Bayview, Green Spring Station, and Skip Viragh cancer outpatient center. Dr. Mehran Habibi is the director Breast center at Johns Hopkins, and he was my breast surgery mentor there. I learned and trained on developing breast centers and hands-on practice on the latest breast cancer surgery tools available at Johns Hopkins like Margin Probe, Endomag, axillary surgery updates, and Oncoplastic procedures. Johns Hopkins’s latest research on breast cancer diagnosis and treatments, including their liquid DNA biopsies for breast cancer recurrences and much more practice-changing trends over there, this clinical observership boosted my confidence as a Breast Surgical Oncologist. This collaboration is a perfect opportunity for the young consultants to learn from the latest evidence-based practices and broaden their professional horizons.” ~ Dr Sadaf Ishaque Here what they have to say about their visit and learning over there. It was a refresher for “best practice.” Including value-added services in Shalamar Hospital and frequent communication with the JHMI consultants and administration will pave the way for patient benefit in the future. I would add that since my expectations and learning objectives were evident before my visit, hence it maximized my experience there. I recommend the same for the consultants visiting in the next phase.” ~Dr Eisha Tahir
Dr Maryam Riaz Tarar Representing Pakistan at the 36th Meeting of the WHO Eastern Mediterranean Regional Commission for Certification of Poliomyelitis Eradication.

Shalamar Institute of Health Sciences (SIHS) is proud to announce that Dr. Maryam R Tarar, Professor of Pathology, Convener Infection Prevention & Control Committee (IPCC), and frontline team leader in fighting COVID-19, was nominated by the government and World Health Organization (WHO) to represent Pakistan at the 36th meeting of the “Eastern-Mediterranean Regional Commission for Certification of Poliomyelitis Eradication (EM/RCC).” The EM/RCC meets annually to discuss the data on polio eradication from 22 member states. The report to discuss this data is presented by National Certification Committee (NCC) Chair or a nominated member from each country. For this meeting held at Dusit Thani Hotel, Dubai, from 31st May to 2nd June, Prof. Tarar was nominated to present the Annual Progress Report for the year 2021 as a member of NCC Pakistan. The other team members comprised Pakistan WHO Team Lead Dr. Zainul Abedin Khan and National Poliovirus Surveillance Coordinator Dr. Shafique-ur-Rehman. The presentation covered five key subtopics: polio eradication strategies; the number of isolates of wild poliovirus (WPV) and vaccine-derived poliovirus (VDPV2) isolates; environmental surveillance network; surveillance of acute flaccid paralysis (AFP) cases and poliovirus containment. The session on day 2 of the meeting provided to Pakistan and Afghanistan was one of the most extended and in-depth due to the endemic nature of poliomyelitis in the country. Prof Tarar received praise from WHO/EMRO Focal points/coordinator, Ms. Rasha Naguib, and other country representatives for her poise and speaking style as the “Face of Pakistan.” Prof. Maryam Tarar also attended the Training of the EM National Users (MoH Focal Persons/NCC) for Poliomyelitis Eradication – Electronic Annual Certification Reports System (e-ACR). This was mandated for chairs of NCC. This three-day course focused on providing the participants with all information necessary to report their findings from next year onwards digitally. As a representative of Pakistan, Professor Tarar will now act as a trainer for others in Pakistan on using eACR.